IXICO plc Correction of clerical error
22 Octubre 2024 - 9:00AM
RNS Regulatory News
RNS Number : 1760J
IXICO plc
22 October 2024
22 October 2024
IXICO PLC
("IXICO" or
the "Company")
Correction of clerical
error
IXICO plc (AIM: IXI), has become
aware of a clerical error in resolutions 1 and 3 (the
"Resolutions") as set out in the notice of general meeting
accompanying the circular sent to shareholders dated 9 October 2024
(the "Circular") convening a general meeting for 25 October 2024
(the "General Meeting"). The Resolutions seek shareholder authority
to issue the New Ordinary Shares in connection with the
Fundraising. The aggregate nominal value of shares referred to in
the Resolutions should have been £447,368.42 rather than £42,500.
This corrected figure is consistent with the figures relating to
the Fundraising set out elsewhere in the Circular.
In accordance with its articles of
association the Company intends to propose additional ordinary
resolutions at the General Meeting to amend the Resolutions and
correct this error.
Shareholders do not need to take any
further action in relation to the business to be conducted at the
Meeting.
Defined terms used in this
announcement have the meanings given to them in the Circular unless
otherwise stated.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited
(Nominated adviser and sole broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan
Hodkinson (Corporate
Finance)
|
|
|
Nigel Birks (Life Sciences
Specialist Sales)
|
|
|
Harriet Ward (Corporate
Broking)
|
|
|
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com and follow us on X
(formerly Twitter) @IXICOnews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCKZMZGFZKGDZM
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
